Our future prospective studies can further compare the efficacy among MRD-directed preemptive Chemo-DLI, IFN-α treatment, MoAbs, and CAR-T therapy in ALL patients following allo-HSCT48–50. This evidence concerns the gene IFNA2 and acute lymphoblastic leukemia.